['graft versus host disease']
['ibrutinib']

        Inclusion Criteria:

          -  Steroid dependent or refractory classic chronic GVHD disease.

          -  No more than 3 previous treatments for cGVHD.

          -  Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study
             entry.

          -  Men and women ≥18 years old.

          -  Karnofsky performance status ≥60.

        Exclusion Criteria:

          -  Known or suspected active acute GVHD.

          -  Current treatment with sirolimus AND either cyclosporine or tacrolimus.

          -  History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs
             or other cancer chemotherapy in the 4 weeks prior to starting study drug.

          -  Currently active, clinically significant cardiovascular disease.

          -  Uncontrolled infections not responsive to antibiotics, antiviral medicines, or
             antifungal medicines or a recent infection requiring systemic treatment that was
             completed ≤14 days before the first dose of study drug.

          -  Progressive underlying malignant disease including post-transplant lymphoproliferative
             disease.

          -  History of other malignancy (not including the underlying malignancy that was the
             indication for transplant)

          -  Concomitant use of warfarin or other Vitamin K antagonists

          -  Known bleeding disorders or hemophilia.

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

          -  Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus
             (HCV) or hepatitis B virus (HBV).

          -  Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
      